Table 3.

AEs of interest among adolescent patients who applied 1.5% ruxolitinib cream at any time during the 52-week study period^a

	1.5% ruxolitinib cream (n = 114)
Cytopeniasb	2 (1.8)
Neutropenia	2 (1.8)
Viral skin infections	1 (0.9)
Herpes zoster	1 (0.9)
Herpes simplex virus	0
Molluscum contagiosum	0
Lipid elevations	0
Liver enzyme elevations	0
MACE	0
Malignancies	0
Notable serious infections	0
Thrombocytosis	0
Thrombotic events	0

AE adverse event, MACE major adverse cardiovascular event, TEAE treatment-emergent adverse event

^aAcross all patients who initiated in the vehicle-controlled period, even if they discontinued before the long-term safety period. Data are for patients while applying ruxolitinib cream. For patients who switched from vehicle, the period was 44 weeks

^bCytopenias include erythropenia (anemia, microcytic anemia, normocytic anemia, and decreased hemoglobin), neutropenia (neutropenia and neutrophil count decreased), and thrombocytopenia (thrombocytopenia and platelet count decreased)